Objective  To explore the barriers and suggestions for pharmacists in community pharmacies to implement pharmacy services for patients with chronic diseases.

Methods  Barriers and suggestions for developing pharmacy services for chronic diseases were investigated through an online questionnaire and one-on-one interviews with pharmacists in community pharmacies.

Results  A total of 167 community pharmacists participated in the questionnaire survey, and lack of effective communication with other healthcare professionals (67.07%) and lack of government policy support (65.27%) were the biggest barriers identified by pharmacists. A total of 16 community pharmacists were selected for qualitative interviews, lack of corporate policy, legal protection, public awareness, cooperation with other healthcare workers, and professional competence were the main barriers, and accordingly, the reform of the corporate assessment system, the government's investment in continuing education, and the enhancement of individual professional competence were the factors that pharmacists believed could facilitate the implementation of pharmacy services.

Conclusion  Pharmacists in community pharmacies should continue to improve their professionalism to meet the challenges of providing pharmacy services, and the government and corporate management should play more active role in promoting more standardized and in-depth pharmacy services.

1.World Health Organization. World health statistics 2022: monitoring health for the SDGs, sustainable development goals [EB/OL]. (2022-05-25) [2023-06-10] https://cdn.who.int/media/docs/default-source/gho-documents/world-health-statistic-reports/worldhealthstatistics_2022.pdf?sfvrsn=6fbb4d172.

2.袁天蔚, 阮梅花, 朱成姝, 等. 2023年慢性病防控领域发展态势[J]. 生命科学, 2024, 36(1): 30-38. [Yuan TW, Ruan MH, Zhu CS, et al. Progress of prevention and control of chronic diseases in 2023[J]. Chinese Bulletin of Life Sciences, 2024, 36(1): 30-38.] DOI: 10.13376/j.cbls/2024005.

3.国务院办公厅国务院办公厅关于印发中国防治慢性病中长期规划（2017-2025年）的通知[EB/OL].  (2017-02-14) [2023-03-21] https://www.gov.cn/zhengce/content/2017-02/14/content_5167886.htm.

4.Xi X, Huang Y, Lu Q, et al. Community pharmacists' opinions and practice of pharmaceutical care at chain pharmacy and independent pharmacy in China[J]. Int Clin Pharm, 2019, 41(2): 478-487. DOI: 10.1007/s11096-019-00802-w.

5.Manolakis PG, Skelton JB. Pharmacists' contributions to primary care in the United States collaborating to address unmet patient care needs: the emerging role for pharmacists to address the shortage of primary care providers[J]. Am J Pharm Educ, 2010, 74(10): S7. DOI: 10.5688/aj7410s7.

6.Kelling SE. Exploring accessibility of community pharmacy services[J]. Innovations in Pharmacy, 2015, 6(3): 1-4. DOI: 10.24926/iip.v6i3.392.

7.安徽省药师协会. 关于印发《社会药房药学服务规范（试行）》的通知 [EB/OL]. (2020-06-18) [2023-03-06] http://alpa.ahfda.com/alpa/info/page.aspx?id=314.

8.国家药品监督管理局. 关于政协第十三届全国委员会第五次会议第02186号（医疗卫生类199号）提案答复的函 [EB/OL]. (2022-08-04) [2023-03-06] https://www.nmpa.gov.cn/zwgk/jyta/zhxta/20220804100853105.html.

9.张笑雨. 国药控股(湖北): 慢病管理新突破[J]. 中国药店, 2017, (6): 68-70. [Zhang XY. Sinopharm  Group  (Hu bei): new breakthrough in chronic disease management[J]. China Drug Store, 2017, (6): 68-70.] DOI:  CNKI:SUN:YDZZ.0.2017-06-029.

10.李明洙, 张茜, 于东港, 等. 广东某药店利用MTM-AI系统开展慢病管理的案例研究[J]. 中国药业, 2018, 27(18): 76-79. [Li MZ, Zhang Q, Yu DG, et al. A case study of chronic disease management by using MTM-AI systemin a drugstore in Guangdong province[J]. China Pharmaceuticals, 2018, 27(18): 76-79.] DOI: 10.3969/j.issn.1006-4931.2018.18.025.

11.Wang X, Sun X, Birch S, et al. People-centred integrated care in urban China[J]. Bull World Health Organ, 2018, 96(12): 843-852. DOI: 10.2471/blt.18.214908.

12.高明泽. 执业药师药学服务及继续教育的调查研究 [D]. 沈阳: 中国医科大学, 2021.

13.Wang J, Pei Y, Yu F, et al. Understandings, attitudes, and barriers about diabetes care: analysis of factors influencing community pharmacists in China[J]. Diabetes Metab Syndr Obes, 2021, 14: 1999-2009. DOI: 10.2147/dmso.S304066.

14.Yong FR, Hor SY, Bajorek BV. Australian community pharmacy service provision factors, stresses and strains: a qualitative study[J]. Explor Res Clin Soc Pharm, 2023, 9: 100247. DOI: 10.1016/j.rcsop.2023.100247.

15.Jarab AS, Al-Qerem W, Mukattash TL, et al. Pharmacists' knowledge and attitudes toward medication therapy management service and the associated challenges and barriers for its implementation[J]. Saudi Pharm J, 2022, 30(6): 842-848. DOI: 10.1016/j.jsps.2022.03.008.

16.Hashmi FK, Hassali MA, Khalid A, et al. A qualitative study exploring perceptions and attitudes of community pharmacists about extended pharmacy services in Lahore, Pakistan[J]. BMC Health Serv Res, 2017, 17(1): 500. DOI: 10.1186/s12913-017-2442-6.

17.Smith M. Primary Care pharmacist services align with payment reform and provider "Joy of Practice"  [J].  Ann Pharmacother, 2019, 53(3): 311-315. DOI: 10.1177/1060028018807398.

18.杨心玫, 申卫星. 药师立法中的药事服务费问题研究[J]. 中国卫生产业, 2019, 16(17): 94-98, 147. [Yang XM, Shen WX. Study on the pharmacy service fee in the pharmacist legislation[J]. China Health Industry, 2019, 16(17): 94-98, 147.] DOI: 10.16659/j.cnki.1672-5654.2019.17.094.

19.徐敢. 医药分开背景下社会药房药事服务费探索[J]. 中国药事, 2018, 32(11): 1462-1426. [Xu G. Analysis of pharmacy service fee in community pharmacies under the background of separation of medicine and pharmacy[J]. Chinese Pharmaceutical Affairs, 2018, 32(11): 1462-1466.] DOI: 10.16153/j.1002-7777.2018.11.003.

20.American Pharmacists Association, National Association of Chain Drug Stores Foundation. Medication therapy management in pharmacy practice: core elements of an MTM service model (version 2.0)[J]. J Am Pharm Assoc (2003), 2008, 48(3): 341-353. DOI: 10.1331/JAPhA.2008.08514.

21.Bennett M, Goode JV. Recognition of community-based pharmacist practitioners: Essential health care providers  [J]. J Am Pharm Assoc (2003), 2016, 56(5): 580-583. DOI: 10.1016/j.japh.2016.04.566.

22.何兴美, 陆旭萍, 詹寒明, 等. 社区医院医师药师联合门诊工作模式中药学服务的实践和探讨[J]. 中国药事, 2021, 35(6): 681-689. [He XM, Lu XP, Zhan HM, et al. Practice and discussion on the pharmacy service of the joint outpatient service mode of doctors and pharmacists in community hospitals[J]. Chinese Pharmaceutical Affairs, 2021, 35(6): 681-689.] DOI: 10.16153/j.1002-7777.2021.06.011.

23.Madras BK, Compton WM, Avula D, et al. Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: comparison at intake and 6 months later[J]. Drug Alcohol Depend, 2009, 99(1-3): 280-295. DOI: 10.1016/j.drugalcdep.2008.08.003.

24.Meyerson BE, Agley JD, Jayawardene W, et al. Feasibility and acceptability of a proposed pharmacy-based harm reduction intervention to reduce opioid overdose, HIV and hepatitis C[J]. Res Social Adm Pharm, 2020, 16(5): 699-709. DOI: 10.1016/j.sapharm.2019.08.026.

25.Cochran G, Chen Q, Field C, et al. A community pharmacy-led intervention for opioid medication misuse: a small-scale randomized clinical trial[J]. Drug Alcohol Depend, 2019, 205: 107570. DOI: 10.1016/j.drugalcdep.2019.107570.

26.Horsfield E, Sheridan J, Anderson C. What do community pharmacists think about undertaking screening and brief interventions with problem drinkers? Results of a qualitative study in New Zealand and England[J]. Int J Pharm Pract, 2011, 19(3): 192-200. DOI: 10.1111/j.2042-7174.2011.00112.x.

27.Laliberté MC, Perreault S, Damestoy N, et al. Ideal and actual involvement of community pharmacists in health promotion and prevention: a cross-sectional study in Quebec, Canada[J]. BMC Public Health, 2012, 12: 192. DOI: 10.1186/1471-2458-12-192.

28.Fernandes HVJ, Houle SKD. Development and testing of a clinical practice framework for pharmacists to assess patients' travel-related risks: the 5W approach to travel risk identification[J]. Pharmacy (Basel), 2019, 7(4): 159. DOI: 10.3390/pharmacy7040159.

29.Makowsky MJ, Cor K, Wong T. Exploring electronic medical record and self-administered medication risk screening tools in a primary care clinic[J]. J Manag Care Spec Pharm, 2017, 23(5): 566-572. DOI: 10.18553/jmcp.2017.23.5.566.

30.Pestka DL, Paterson NL, brummel AR, et al. Barriers and facilitators to implementing pharmacist-provided comprehensive medication management in primary care transformation[J]. Am J Health Syst Pharm, 2022, 79(15): 1255-1265. DOI: 10.1093/ajhp/zxac104.

31.Awdishu L, Singh RF, Saunders I, et al. Advancing pharmacist collaborative care within academic health systems[J]. Pharmacy (Basel), 2019, 7(4): 142. DOI: 10.3390/pharmacy7040142.

32.喻鹏久, 谭涵梦, 刘亮辉, 等. 某院药师协议处方制度的构建与实践探索[J]. 今日药学, 2018, 28(11): 749-751. [Yu PJ, Tan HM, liu LH, et al. Construction of pharmacist supplementary prescribing system in a hospital[J]. Pharmacy Today, 2018, 28(11): 749-751.] DOI: 10.12048/j.issn.1674-229X.2018.11.008.

33.Saw PS, Nissen L, Freeman C, et al. A qualitative study on pharmacists' perception on integrating pharmacists into private general practitioner's clinics in Malaysia  [J]. Pharm Pract, 2017, 15(3): 971. DOI: 10.18549/ PharmPract.2017.03.971.

34.Tan EC, stewart K, Elliott RA, et al. Stakeholder experiences with general practice pharmacist services: a qualitative study[J]. BMJ Open, 2013, 3(9): e003214. DOI: 10.1136/bmjopen-2013-003214.